Historically, January and February tend to be very strong months for biotech, while March tends to be very weak. But, with COVID-19 continuing to bear down on the entire world, this is no normal time. So will this March buck the trend? Today’s article delves into this question, as well as what’s likely to happen to a company like Moderna after this year’s mass vaccinations, whether Moderna or Pfizer-BioNTech have the mRNA advantage going forward, and what the future of the biotech sector as a whole looks like. For more, CLICK HERE.